-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PPMX-T002 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PPMX-T002 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PPMX-T002 in Triple-Negative Breast Cancer (TNBC) Drug Details: PPMX-T002 (FF-21101)...
-
Product Insights
Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) - Drugs In Development, 2023’, provides an overview of the Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Low-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Low-Grade Glioma - Drugs In Development, 2023’, provides an overview of the Low-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Low-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neurofibromatoses – Drugs In Development, 2023
Global Markets Direct’s, ‘Neurofibromatoses - Drugs In Development, 2023’, provides an overview of the Neurofibromatoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neurofibromatoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Drugs In Development, 2023’, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ursodiol 1 in Liver Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ursodiol 1 in Liver Diseases report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ursodiol 1 in Liver Diseases Drug Details: Ursodiol (DWJ-1464) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirdametinib in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mirdametinib in Melanoma Drug Details: mirdametinib (PD-0325901) is under development for the treatment of neurofibromatosis...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nirogacestat Hydrobromide in Benign Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nirogacestat Hydrobromide in Benign Tumor Drug Details: Nirogacestat hydrobromide (Ogsiveo) acts as an antineoplastic agent....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sucunamostat in Type 2 Diabetes
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sucunamostat in Type 2 Diabetes Drug Details: Sucunamostat (SCO-792) is under development for the treatment...